The NIBL was funded by the International Atomic Energy Agency (IAEA) as part of the Neuroimaging Consortium (NIC) for “Enhancing Capacity of Neuroimaging and Biomarkers: Application in Early-stage Alzheimer's Disease with Comorbidities” to assess imaging biomarkers in possible AD patients of developing countries, (Thailand, Slovenia, South Africa, Bangladesh, India, Argentina, Estonia, and Uruguay) using positron emission tomography (PET) and magnetic resonance imaging (MRI).
